VRTX

Vortex Energy Announces Drilling Update and $115,500 Grant Award At The Robinsons River Salt Project

Retrieved on: 
Tuesday, April 9, 2024
Government, Project, Vortex, FTE, VRTX, Weather

VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) (“Vortex” or the “Company”) is pleased to announce the completion of drill planning for the third exploration drillhole at the Robinsons River Salt Project (the “Project”).

Key Points: 
  • VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) (“Vortex” or the “Company”) is pleased to announce the completion of drill planning for the third exploration drillhole at the Robinsons River Salt Project (the “Project”).
  • Furthermore, Vortex has been awarded a $115,500 grant from the Government of Newfoundland and Labrador, Department of Industry, Energy and Technology Mineral Incentive Program – Junior Exploration Assistance program.
  • This grant is in recognition of prior exploration expenditures made on the Project.
  • Paul Sparkes, CEO of Vortex Energy Corp., commented, “We are thrilled to be advancing our exploration efforts at the Project.

Vortex Energy Closes Charity Flow-Through Private Placement for Gross Proceeds of C$830,000

Retrieved on: 
Tuesday, March 26, 2024
Income Tax Act, Offering, VRTX, Security (finance)

VANCOUVER, British Columbia, March 26, 2024 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) ("Vortex” or the "Company") is pleased to announce that it has closed its previously announced non-brokered charity flow-through private placement of common shares of the Company (the “Offering”) for gross proceeds to the Company of C$830,000.52 pursuant to an arrangement with Wealth Creation Preservation & Donation Inc. (“WCPD”).

Key Points: 
  • VANCOUVER, British Columbia, March 26, 2024 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) ("Vortex” or the "Company") is pleased to announce that it has closed its previously announced non-brokered charity flow-through private placement of common shares of the Company (the “Offering”) for gross proceeds to the Company of C$830,000.52 pursuant to an arrangement with Wealth Creation Preservation & Donation Inc. (“WCPD”).
  • Pursuant to the Offering, the Company issued 2,441,178 “flow-through” common shares of the Company (each, a “Flow-Through Share”) at a price of C$0.34 per Flow-Through Share.
  • The Flow-Through Shares issued under the Offering are intended to qualify as “flow through shares” within the meaning of the Income Tax Act (Canada) (the “Tax Act”).
  • All securities issued in connection with the closing of the Offering are subject to a statutory hold period, in accordance with applicable securities laws, expiring on July 26th, 2024.

Vertex to Announce First Quarter 2024 Financial Results on May 6

Retrieved on: 
Tuesday, April 9, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, International, Webcast, Vertex Pharmaceuticals, Vertex, VRTX

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close.
  • The company will host a conference call and webcast at 4:30 p.m.
  • To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals First Quarter 2024 Earnings Call.”
    The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section.
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease

Retrieved on: 
Monday, April 1, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, BTD, Orphan drug, APOL1, RPD, Disease, Patient, Apolipoprotein L1, FSGS, Standard of care, EMA, UPCR, European Medicines Agency, Vertex Pharmaceuticals, Clinical trial, Vertex, Proteinuria, Food, FDA, IDMC, VRTX, Pharmaceutical industry

The clinical trial is designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with proteinuric kidney disease mediated by two variants in the APOL1 gene, known as AMKD.

Key Points: 
  • The clinical trial is designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with proteinuric kidney disease mediated by two variants in the APOL1 gene, known as AMKD.
  • In addition, the trial has been expanded to include adolescents with AMKD ages 10 to 17 years.
  • The IDMC also recommended enrolling adolescents with AMKD ages 10 to 17 years in the Phase 3 portion of the study.
  • The European Medicines Agency (EMA) has also granted inaxaplin Priority Medicines (PRIME) and Orphan Drug designations for AMKD.

Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Retrieved on: 
Thursday, March 21, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, Clinical Trials, Death, Autosome, VRTX, Growth, Disease, PC1, Patient, Kidney failure, Kidney transplantation, Polycystic kidney disease, IND, Vertex Pharmaceuticals, PKD1, Vertex, ADPKD, Dialysis, Cystic fibrosis, Food, Pharmaceutical industry

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease (ADPKD) in patients with a subset of PKD1 genetic variants.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease (ADPKD) in patients with a subset of PKD1 genetic variants.
  • ADPKD is the most common inherited kidney disease, with an estimated 250,000 people in the U.S. and Europe living with ADPKD; however, there are no treatments currently available that address the underlying causal biology of the disease.
  • ADPKD is a life-shortening genetic kidney disease characterized by the growth of numerous kidney-enlarging cysts that impair kidney function and can ultimately lead to kidney failure, requiring dialysis or kidney transplantation, and premature death.
  • The majority of ADPKD cases are caused by variants in the PKD1 gene, which encodes the polycystin 1 (PC1) protein.

Vortex Energy Announces $830,000 Charity Flow Through Offering

Retrieved on: 
Monday, March 4, 2024
Person, CS, Income Tax Act, VRTX, News, Legislation, FT, Security (finance)

VANCOUVER, British Columbia, March 04, 2024 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) ("Vortex” or the "Company") is pleased to announce that it intends to complete a non-brokered charity flow through private placement of 2,441,178 common shares of the Company (“CS“) at a price of $0.34 per CS for aggregate gross proceeds of approximately $830,000.52 (“FT Offering“). The CS issued under the FT Offering are intended to qualify as “flow through shares” within the meaning of the Income Tax Act (Canada) (the “Tax Act”).

Key Points: 
  • The CS issued under the FT Offering are intended to qualify as “flow through shares” within the meaning of the Income Tax Act (Canada) (the “Tax Act”).
  • Subject to compliance with the policies of the Canadian Securities Exchange (“CSE“) and applicable securities legislation, the Company may pay finder’s fees in connection with the FT Offering‎.
  • Closing of the FT Offering is subject to the Company’s receipt of all necessary regulatory approvals, including approval of the Canadian Securities Exchange.
  • The securities issued pursuant to the FT Offering will be subject to a four-month hold period from the closing date.

Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older

Retrieved on: 
Friday, February 23, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Committee, Cystic fibrosis, VRTX, Vertex, European, Vertex Pharmaceuticals, CHMP, CFTR, Disease, Medication

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants with cystic fibrosis (CF) ages 1 month to less than 4 months old who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

Key Points: 
  • Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants with cystic fibrosis (CF) ages 1 month to less than 4 months old who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
  • “Cystic fibrosis is a chronic, progressive disease that is present from birth, which is why it is important to treat the underlying cause of this disease as early as possible to potentially slow disease progression,” said Fosca De Iorio, Vice President, International Medical Affairs at Vertex.
  • “If the label expansion for KALYDECO is approved, this would allow eligible infants with CF to receive a treatment that targets the underlying cause of their disease at the very start of their lives.”
    In the European Union, KALYDECO® is already approved for the treatment of people with CF ages 4 months old and above with specific mutations in the CFTR gene.

Vertex to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, February 20, 2024
Biotechnology, Pharmaceutical, Genetics, Health, VRTX, News, Conference, Global Research, Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Charles Wagner, Executive Vice President and Chief Financial Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer, will participate in two upcoming investor conferences:

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Charles Wagner, Executive Vice President and Chief Financial Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer, will participate in two upcoming investor conferences:
    TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 10:30 a.m.
  • Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 4:00 p.m.
  • A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page.
  • A replay of the conference webcast will be archived on the company's website.

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Retrieved on: 
Tuesday, February 13, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hospital, European Commission, CRISPR, Volatile organic compound, Hematology, Gene, HSC, VRTX, TDT, SCD, European, Civil service commission, Haematopoietic system, Patient, Sickle cell disease, Bambino, Catholic higher education, Pediatrics, Vertex Pharmaceuticals, Pharmaceutical industry

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy.
  • CASGEVY is the only genetic therapy approved for SCD and TDT patients in the European Union (EU) and with this approval, there are now more than 8,000 patients potentially eligible for treatment.
  • Through this work, Vertex has secured early access for eligible TDT patients in France ahead of the national reimbursement process.
  • Vertex continues to engage with hospitals experienced in stem cell transplantation to establish a network of independently operated authorized treatment centers (ATCs) for the administration of CASGEVY.

Vortex Energy Corp. Provides Update on Drilling at the Robinsons River Salt Project

Retrieved on: 
Wednesday, February 7, 2024
Overalls, VRTX, Obstruction, Anomaly, Water, Labrador, National instrument

VANCOUVER, British Columbia, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) ("Vortex" or the "Company"), provides an update on drilling of the second approved core well at its Robinsons River Salt Project, located near Stephenville, Newfoundland & Labrador.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) ("Vortex" or the "Company"), provides an update on drilling of the second approved core well at its Robinsons River Salt Project, located near Stephenville, Newfoundland & Labrador.
  • The Company commenced drilling on the second core well on January 16, 2024, which was drilled in the western gravity anomaly at the Robinsons River Salt Project.
  • However, the Company was required to halt drilling because of a hydraulic pump failure which necessitated repairs.
  • During the time drilling was halted, the open hole's condition worsened as the soft sediments interacted with water in the hole.